Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond.
Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond.
复制标题
DOI：
10.3390/curroncol30040323
复制
发表时间：
2023-04-19
期刊：
影响因子：
2.6
通讯作者：
Barata, Pedro C.
中科院分区：
文献类型：
--
作者：
Lanka, Sree M.;Zorko, Nicholas A.;Antonarakis, Emmanuel S.;Barata, Pedro C.
关键词：
随着免疫检查点抑制剂(ICIS)的发展，几种泌尿生殖系统恶性肿瘤的治疗格局已经发生了革命性的变化；然而，免疫疗法在前列腺癌中的应用一直受到限制，部分原因是前列腺癌在免疫方面的“冷”肿瘤地形。到目前为止，pembrolizumab是唯一被批准用于治疗转移性去势抵抗前列腺癌(MCRPC)的免疫检查点抑制剂，这些患者具有高微卫星不稳定性(MSI-H)、错配修复缺陷(DMMR)或高肿瘤突变负荷(TMB)。展望未来，与ICIS的几种组合方法正在探索一种潜在的协同效应，这些方法涉及放射性配体、放射治疗、PARP抑制剂、白细胞介素类抑制剂和癌症疫苗。此外，B7-H3是一种替代检查点，有望增加mCRPC的治疗前景。本文综述了ICIS以往的单一治疗和联合治疗试验，以及免疫治疗联合治疗mCRPC的新策略和治疗靶点。
The therapeutic landscape of several genitourinary malignancies has been revolutionized by the development of immune checkpoint inhibitors (ICIs); however, the utility of immunotherapies in prostate cancer has been limited, partly due to the immunologically “cold” tumor terrain of prostate cancer. As of today, pembrolizumab is the only immune checkpoint inhibitor approved for the treatment of metastatic castration resistant prostate cancer (mCRPC) in a select group of patients with high microsatellite instability (MSI-H), deficient mismatch repair (dMMR), or high tumor mutational burden (TMB). Looking ahead, several combinatorial approaches with ICIs involving radioligands, radiotherapy, PARP inhibitors, interleukin inhibitors, and cancer vaccines are exploring a potential synergistic effect. Furthermore, B7-H3 is an alternative checkpoint that may hold promise in adding to the treatment landscape of mCRPC. This review aims to summarize previous monotherapy and combination therapy trials of ICIs as well as novel immunotherapy combination therapeutic strategies and treatment targets in mCRPC.
登录
查看更多内容
影响因子：
10.9
作者：
Dorff T;Hirasawa Y;Acoba J;Pagano I;Tamura D;Pal S;Zhang M;Waitz R;Dhal A;Haynes W;Shon J;Scholz M;Furuya H;Chan OTM;Huang J;Rosser C
通讯作者：
Rosser C
影响因子：
4
作者：
LeVee A;Lin CY;Posadas E;Figlin R;Bhowmick NA;Di Vizio D;Ellis L;Rosser CJ;Freeman MR;Theodorescu D;Freedland SJ;Gong J
通讯作者：
Gong J
影响因子：
9.3
作者：
Czernin, Johannes;Current, Kyle;Luckerath, Katharina
通讯作者：
Luckerath, Katharina
影响因子：
9.3
作者：
Bellavia, Michael C.;Patel, Ravi B.;Anderson, Carolyn J.
通讯作者：
Anderson, Carolyn J.
影响因子：
10.9
作者：
Karzai, Fatima;VanderWeele, David;Dahut, William L.
通讯作者：
Dahut, William L.